By Medistem - Apr 24, 2009 -
(HealthNewsDigest.com) - San Diego, CA- Medistem Inc announced today publication of a peer reviewed paper describing the scientific rationale and preliminary results of three patients with multiple sclerosis treated with their own fat derived stem cells. (Pictured: Dr. Robert Harman CEO of Vet-Stem)
“In addition to our endometrial regenerative cell (ERC) universal donor stem cell technology, for which an IND has been filed, Medistem has been committed to developing a pipeline of therapeutic products, including in the area of immune modulation” Said Thomas Ichim, CEO of Medistem. “Given our previous observations and IP filings that a stem cell-rich component of adipose tissue, called the Stromal Vascular Fraction, can concurrently immune modulate, while inducing regenerative activities, we are pleased to see the clinical translation of this approach into multiple sclerosis patients.”
>> Continue reading directly from the Health News Digest website.
Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You